The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). - Wikidata - awgldk - TriplyDB

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

http://www.wikidata.org/entity/Q38593365

about

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.Surrogate end points in early prostate cancer clinical states: ready for implementation?Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

P2860

Q26771537-2B72954F-A9B0-4E45-93A4-92AC92BFB8C2 Q38382252-F9C97E83-9AC8-4CA2-A70E-DDC240BCF79B Q38630553-A8A03D4C-B86C-4364-8991-C33E231E432A Q38966736-CE5B2D29-FA50-47BD-8A85-12EEF8CF4578 Q47102678-F8C8B72F-AB7A-42C5-B239-F83A9030427A Q47269814-BE7B13FF-36C1-4B89-8FFC-1664CD0A3AF0 Q48629219-01D1556C-EE26-49D2-9B89-ECF74D13DB90

P2860

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

http://www.wikidata.org/entity/Q38593365

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

@en

type

label

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

@en

prefLabel

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

@en

P1433

Q38593365-BB53EEED-7103-4073-80AB-3F6CE7352659

P1476

Q38593365-34D52FE0-A6C3-44BA-B46E-B101327EF22F

P2093

Q38593365-0A6D4090-41D3-43D9-90DE-16F8D001F343

Q38593365-1071F7D9-3A77-4189-85C2-7FCDEDF44E86

Q38593365-3116BD95-00C9-4DEB-9DAA-86D0A9FF813E

Q38593365-65BC6505-7E85-4D11-88A7-69116D2790CC

Q38593365-8D418259-CA75-4AC9-A6AC-437311E69B8B

Q38593365-95127A10-B3FF-4110-B359-92C64B9120A7

Q38593365-A9A050CB-5BD6-4C2F-8C10-CA51A3BA06F0

Q38593365-B9305CD7-DD2F-423E-BCD3-60191AA6F2DB

Q38593365-D2EE68FE-4DE9-4352-A1BC-5E0F01E3B9BE

Q38593365-E2A3FE47-F2B6-4F8D-BE2B-2C2AC0B4508F

P2860

Q38593365-137AF975-00C2-48D6-8431-AA2328BF04DE

Q38593365-2C22155B-CC82-474E-B233-2D528C1D9F7C

Q38593365-2EA7C590-804B-4DB6-BE25-6E85C9E683F5

Q38593365-3ACA17B6-1603-4403-8EBB-B0617D9B69BE

Q38593365-3E975F18-7CB5-4C51-A5C0-923CFF150B3C

Q38593365-473F4C01-FD4D-40CD-BC81-9D02C4AD2E9C

Q38593365-5CE309DB-34CD-4A47-AD5A-9F3772D38EFF

Q38593365-5EF2D874-5E88-4DA1-A132-0F96F68F0561

Q38593365-6356DFCB-3359-40B1-B8D6-530CE6DE039D

Q38593365-65A44BD3-D17D-446F-BCF9-F87659BBE6B2

P304

Q38593365-DB47B2E9-134C-4535-BE0D-4A4268CC152D

P31

Q38593365-74E89C28-2410-44B7-AADC-C7928B8EACE6

Q38593365-cebfd68b-5e93-4189-b995-55bd348e3bfc

P356

Q38593365-FC8398E3-B076-45E7-B96B-6331513AE597

P407

Q38593365-A6173DD8-6B26-49D2-AF14-96BCA484A35B

P433

Q38593365-5D940F2D-ACF0-4693-BA74-444BCE051924

P478

Q38593365-5A56A7F3-4A5F-4EC8-876C-DE9011AA4946

P50

Q38593365-3AF3FF11-C7E2-4457-BF04-2E2471DE2BC4

Q38593365-52383436-3A5B-4785-9A6B-036A9C118A47

Q38593365-C8DDF21C-0DDE-4110-99F0-C3DB565510C8

P577

Q38593365-B2ACBACC-F294-49DD-BCE6-4A53D128610C

P698

Q38593365-C68FAEF3-D15A-4305-9E77-DE30B95B9C8F

P932

Q38593365-FDD8151E-A59F-47EA-A317-9A0E1C10505F

P356

P1433

Journal of the National Cancer Institute

P1476

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

@en

P2093

A Oliver Sartor

http://www.w3.org/2001/XMLSchema#string

Brandon Mahal

http://www.w3.org/2001/XMLSchema#string

Christopher Sweeney

http://www.w3.org/2001/XMLSchema#string

Howard Soule

http://www.w3.org/2001/XMLSchema#string

ICECaP Working Group

http://www.w3.org/2001/XMLSchema#string

Julia Hayes

http://www.w3.org/2001/XMLSchema#string

Marc Buyse

http://www.w3.org/2001/XMLSchema#string

Meredith Regan

http://www.w3.org/2001/XMLSchema#string

Nancy Keating

http://www.w3.org/2001/XMLSchema#string

Suhui Li

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Cancer statistics, 2014

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.

P304

djv261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJV261

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

Mari Nakabayashi

P577

2015-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26409187

http://www.w3.org/2001/XMLSchema#string

P932

5964738

http://www.w3.org/2001/XMLSchema#string